US Archives - Page 130 of 157 - European Medical Journal

Emerging Artemisinin Resistance in Severe Malaria

A new study highlights partial resistance to artemisinin in Ugandan children with severe malaria, raising concerns about the efficacy of frontline treatments in sub-Saharan Africa.

Novel Steroid-Sparing SLE Solution: ACR24

Evidence supporting a novel therapeutic target for systemic lupus erythematosus (SLE), the E3 ubiquitin ligase “E3-X”, was presented at ACR Convergence 2024 in Washington, D.C.

PI3K Pathway Identified as Key in SSc Skin Fibrosis: ACR2024

Researchers unveiled a groundbreaking study shedding light on the complex molecular interplay driving fibrosis in diffuse systemic sclerosis (dcSSc) at ACR 2024 in Washington, D.C., USA.

Cellular Impacts In Antisynthetase Syndrome: ACR24

New research into how antisynthetase autoantibodies disrupt critical enzymatic functions in muscle cells was presented as part of a plenary abstract session at ACR Convergence 2024 in Washington, D.C.

RISE-Registry Enrollment Elevates Care Quality: ACR24

Participation in the Rheumatology Informatics System for Effectiveness (RISE), an electronic heath record (EHR)-enabled registry designed by the American College of Rheumatology (ACR), significantly improves clinical care metrics, according to a study presented at ACR Convergence 2024.

Breakthrough in Hodgkin’s Treatment: Nivolumab+AVD

A new Phase III clinical trial has revealed that combining nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) improves progression-free survival in patients with Stage III or IV classic Hodgkin’s lymphoma compared to the standard brentuximab vedotin with AVD (BV+AVD).

Air Quality and Eczema: New Health Findings

A recent study has found a significant association between fine particulate air pollution (PM2.5) and eczema, highlighting a potential environmental driver of the skin condition among American adults.

Efficacy and Safety of Upadacitinib in SELECT-GCA Phase III Trial Results: ACR24

A Phase III clinical trial presented at ACR Convergence 2024 revealed that upadacitinib (UPA), combined with a 26-week glucocorticoid (GC) improved disease control and reduced steroid exposure compared to a placebo (PBO) regimen in patients with giant cell arteritis (GCA).

Global Recruiting Patterns Linked To Placebo Responses in PsA Clinical Trials: ACR24

Presented at the ACR Convergence 2024, new research highlighted how changing global recruitment patterns influence placebo response rates in clinical trials for psoriatic arthritis (PsA).

Local Dengue Cases Drive Rapid Public Health Measures

In October 2023, a confirmed local dengue case in Pasadena, California marked a concerning milestone for the state’s public health officials.